NASDAQ:THTX - Theratechnologies Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.13
  • Forecasted Upside: 247.56 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.05
▼ -0.01 (-0.49%)
1 month | 3 months | 12 months
Get New Theratechnologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for THTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for THTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$7.13
▲ +247.56% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Theratechnologies in the last 3 months. The average price target is $7.13, with a high forecast of $11.00 and a low forecast of $2.00. The average price target represents a 247.56% upside from the last price of $2.05.
Buy
The current consensus among 4 polled investment analysts is to buy stock in Theratechnologies.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/3/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/1/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/28/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/24/2020

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/16/2020MackieReiterated RatingBuy$4.50High
i
7/20/2020Royal Bank of CanadaReiterated RatingHold$2.00Low
i
7/13/2020Canaccord GenuityReiterated RatingBuyLow
i
7/8/2020Echelon Wealth PartnersReiterated RatingBuy$11.00High
i
6/24/2020Canaccord GenuityReiterated RatingBuy$11.00Low
i
4/15/2020Canaccord GenuityLower Price TargetBuy$12.00 ➝ $11.00Medium
i
3/3/2020Canaccord GenuityReiterated RatingBuy$95.50High
i
2/26/2020Canaccord GenuityUpgradeBuyLow
i
2/25/2020MackieReiterated RatingBuy$5.80Low
i
Rating by Andre Uddin at Mackie
12/11/2019MackieUpgradeHold ➝ BuyLow
i
12/2/2019Canaccord GenuityInitiated CoverageBuyHigh
i
(Data available from 10/24/2015 forward)
Theratechnologies logo
Theratechnologies Inc., a biopharmaceutical company, markets prescription products in the United States, Europe, and Canada. It offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. The company's pipeline products include F8 Formulation that could be used for the treatment of HIV-associated lipodystrophy; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was founded in 1993 and is headquartered in Montreal, Canada.
Read More

Today's Range

Now: $2.05
$2.01
$2.08

50 Day Range

MA: $2.32
$2.06
$2.62

52 Week Range

Now: $2.05
$1.33
$4.20

Volume

64,425 shs

Average Volume

82,372 shs

Market Capitalization

$157.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.5